Can-Fite BioPharma American Depositary Shares (CANF)

• Market cap: $5.25M
• 1 day: -2.2%
• 5 days: -10.29%
• 1 month: 9.26%
• 3 months: -53.32%
• 6 months: -70.34%
• Year to date: -8.86%
• 1 year: -87.06%
• 5 years: -98.99%
• 10 years: -99.94%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.

Employees: 5